Can an antiviral make radiation more effective against cervical cancer?
NCT ID NCT02515877
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This phase 1 trial is testing whether adding the antiviral drug Vistide (cidofovir) to the standard combination of radiation and chemotherapy can improve outcomes for people with HPV-positive cervical cancer. The idea is that Vistide may make cancer cells more sensitive to radiation by interfering with the viral proteins that help the cancer grow. The study includes about 15 adults with advanced cervical cancer and will focus on finding the safest dose and understanding side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vistide (cidofovir) combined with standard external radiotherapy, brachytherapy, and carboplatin chemotherapy
- What this could lead to
- If successful, this approach could enhance the effectiveness of standard radiochemotherapy for cervical cancer, potentially improving local control and survival rates.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits are uncertain. The antiviral may not enhance treatment as hoped, and there is a risk of increased side effects from the combination.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gustave Roussy Cancer Campus Grand Paris
Villejuif, Val de Marne, 94805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can robotic surgery match open surgery in beating cervical cancer?
- Blood test clues could sharpen cervical cancer treatment
- Can a new drug rally the immune system against Hard-to-Treat cancers?